Publication Name	World Journal of Clinical Urology
Manuscript ID	10718
Country	United States

Received	2014-04-16 09:01
Peer-Review Started	2014-04-16 13:21
To Make the First Decision	2014-06-18 18:34
Return for Revision	2014-06-19 10:14
Revised	2014-06-26 02:56
Second Decision	2014-07-29 09:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-07-29 10:02
Articles in Press	2014-07-29 10:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-17 08:35
Publish the Manuscript Online	2014-11-19 17:43

ISSN	2219-2816 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Review
Article Title	Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists
Manuscript Source	Invited Manuscript
All Author List	Petra Popovics, Andrew V Schally, Norman L Block and Ferenc G Rick
Funding Agency and Grant Number	Funding Agency Grant Number Urology Care Foundation Research Scholars Program and the American Urological Association (AUA) Southeastern Section to Rick FG, in part Department of Medicine, Dresden Helmholtz Alliance ICEMED (Imaging and Curing Environmental Metabolic Diseases) through the Initiative and Networking Fund of the Helmholtz Association to Popovics P L Austin Weeks Endowment for Urologic Research to Block NL Medical Research Service of the Veterans Affairs Department, Departments of Pathology and Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, the South Florida Veterans Affairs Foundation for Research and Education to Schally AV
Corresponding Author	Ferenc G Rick, MD, PhD, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Research (151) 2A127, 1201 NW 16th St, Miami, FL 33125, United States. ferencrick@gmail.com
Key Words	Benign prostatic hyperplasia; Luteinizing hormone-releasing hormone; Growth hormone-releasing hormone; Gastrin-releasing peptide; Somatostatin; Targeted therapy
Core Tip	A new, effective treatment for benign prostatic hyperplasia (BPH) is critically needed. Present side effects of therapy include impotence, decreased libido, abnormal ejaculation, dizziness, weakness, blurred vision and insomnia. Preclinical data suggest that antagonists of neuropeptides growth hormone-releasing hormone, luteinizing hormone-releasing hormone and gastrin-releasing peptide are effective in shrinking prostates in part by suppressing growth factors and inflammatory cytokines. Their effect is exerted through a decrease in levels of circulating hormones and also on a direct action on their respective prostatic receptors. These analogs seem to have the same clinical effects as the currently available BPH medical therapies but possess greater efficacy and have fewer or no side effects.
Publish Date	2014-11-19 17:43
Citation	Popovics P, Schally AV, Block NL, Rick FG. Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists. World J Clin Urol 2014; 3(3): 184-194
URL	http://www.wjgnet.com/2219-2816/full/v3/i3/184.htm
DOI	http://dx.doi.org/10.5410/wjcu.v3.i3.184

Full Article (PDF)	WJCU-3-184.pdf
Full Article (Word)	WJCU-3-184.doc
Manuscript File	10718-Review.docx
Answering Reviewers	10718-Answering reviewers.pdf
Copyright License Agreement	10718-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	10718-Language certificate.pdf
Peer-review Report	10718-Peer review(s).pdf
Scientific Misconduct Check	10718-CrossCheck.jpg
Scientific Editor Work List	10718-Scientific editor work list.pdf